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Introduction
Colorectal cancer is a major cause of death in We-
stern countries (Europe and United States) (1), In
Asian countries, e.g. Hong Kong, it is the second lea-
ding cause od death (2). The prognosis of colorectal
cancer is related to the stage of the disease and the de-
cision of a potential, invasive examination is contin-
gent upon a colorectal staging system. Tumours within
the intestinal wall (T1 and T2) are generally conside-
red to be early cancer. The prevalence of T1 and T2
cancers has been assessed in a number of publications
that showed 12% of colorectal tumours removed by
endoscopic polypectomy and 10% by radical surgery
(3-5). 
Patients diagnosed with T1 and T2 colorectal
cancer are believed to have a good prognosis. Howe-
ver, possible local relapses, especially of rectal can-
cers, or even distant metastases are still present. In-
deed, the prognostic survival and/or relapse factors in
patients with T1 and T2 stage cancers are not yet well
defined. 
The purpose of this study has been to analyze the
characteristics of pT1 and pT2 stage colorectal cancer
and to determine the risk factors that may affect the
survival of or relapse in patients with colorectal cancer
at this stage treated with radical surgery. 
Patients and methods
From January 2001 to December 2005, we operated on 68 pa-
tients (36 men and 32 women) with pT1 and pT2 cancer. The
study excluded patients with family polyposis, intestinal inflam-
matory disorders, synchronous or metachronous tumours, with
post- palliative resection status. The diagnosis of colorectal neopla-
sia followed a colonoscopy with biopsy.  
Patients underwent surgical resection in laparotomy or laparo-
scopy. Hemicolectomy or colon resection (in laparotomy or laparo-
scopy) was performed with lymphadenectomy according to onco-
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logical principles. For middle or low rectal tumours, a mesorectomy
was performed according to the classic surgery technique described
by various Authors (6-8). The surgical specimen is examined accor-
ding to the guidelines of AJCC (American Joint Committee on
Cancer) and UICC (International Union Against Cancer). 
In the first two years, the patients were followed up every 2-3
months, and every 4 months in the third year. Subsequently, the
patients were followed up annually. The follow-up consisted of
anamnesis, physical exam, blood tests, and CEA test. The colono-
scopy was performed at regular intervals. For rectal cancer, a digi-
tal rectal examination was performed at each visit to detect possi-
ble anastomotic stenosis or local recurrence. For suspect recurren-
ces, endoscopy and  CT scan were performed.
Results
This study enrolled 68 patients (36 men and 32
women). The mean age was 58 years (range 38-79).
Of the 68 patients, 23 had a T1 and 45 a T2 tumor.
Within T1 tumours we found a rectal localization in
15 patients and a colon localization in 8 patients;
within T2 tumours we found a rectal localization in 21
patients and a colon localization in 24 patients. 
All patients were treated surgically with radical exe-
resis and intent to treat. The margin sections of all re-
sections were tumour-free. In Table I, gender, age, lo-
calization, histological type differentiation, lymph no-
de status, follow up average time, survival at 2 and 5
years were compared in patients with T1 and T2. 
Both genders were similarly represented: 18 men
and 14 women had colon cancer, while 18 men and 18
women had rectal cancer; the mean age for colon can-
cer was 46 (range 38-67 years) and 61 (range 42-79
years) for rectal cancer. 
The lymph node metastases were few both in colon
cancer (9) and in rectal cancer (10). 
The percentage of survival at 2 and 5 years was
rather high: 91% at 2 years and 88% at 5 years for co-
lon cancer, 90% at 2 years and 84% at 5 years for rec-
tal cancer. Average follow up was 47 months for the
colon and 42 months for the rectum. 
Three patients died in the immediate postoperati-
ve for non tumoral pathologies and were not included
in this study. No significant differences in survival we-
re observed for each type of tumour. 
With reference to the rectal cancer group, we had
10 patients with tumour of the rectal sigmoid junc-
tion, 18 patients with tumours of the middle rectum
and 8 patients with tumour of the low rectum. No
particular statistical difference was reported in the per-
centage of survival at 2 and 5 years. 
As Table 1 shows, among colon cancer patients 5
had tumour with lymph nodes metastases and, among
rectal cancer patients, 8 had lymph node metastases.
No significant difference was reported in survival at 2
and 5 years among the two groups of patients. 
Discussion
The colorectal intramural tumour (T1 and T2) is
considered early and associated with a favourable pro-
gnosis. The presence of the tumour at the mucosa le-
vel or the invasion of the submucosa clearly can pro-
duce a higher possibility of lymph node metastases,
though the percentage of lymph nodes affected is
rather low (15%-22%). Sitzler et al. in a Singapore
study has reported a similar incidence of lymph node
metastases in T1 (5.7%) and T2 (19.7%) (11-14). 
The incidence of lymph node metastases in T1
cancers appears to be low also with  incidences of 8%-
16% reported in other studies (15-17). This is due
probably to the low number of lymph nodes examined
in T1 tumours, as also the small number of lymph no-
des found in T2 cancer patients. Kawamma et al. (13)
show that 92% of patients with lymph node metasta-
ses in T1 colon cancer has only a potential risk of can-
cer dissemination.
Thus, clearly the invasion at lymph node level is
lower in early cancer and the prognosis is favourable
especially if a radical surgery with lymphadenectomy is
performed (18). 
In the literature we have noted that many studies
have examined the presence of lymph node metastases
as a predictive factor (19-20). In our study, the corre-
lation between lymph node metastases and  survival at
2 and 5 years shows that lymph node invasion is stric-
tly related to survival. Okabe et al. also demonstrated
that lymph node metastases were significantly more
common in the rectum (15%) than in the left (8%) or
right colon (3%). These varying percentages may be the
TABLE 1 - RESULTS
Colon Rectum
T1, n (%) 8 (35%) 15 (65%)
T2, n (%) 24 (53%) 21 (47%)
Mean age (years) 46 (38-67) 61 (42-79)
Gender U 18/D 14 U 18/D 18
Lymph node 5 (15%) 8 (22%)
metastases, n (%)
Survival at 2 years 91% 90%





Follow Up (months) 47 42 
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result of differences in population of patients at various
institutions. In our study, the survival at 2 and 5 years
is 91% and 88% for colon cancer, while for the rectal
cancer is, respectively, 90% and 84%. We don’t find
any difference of survival between T1 and T2. 
The type of intramural invasion did not change the
oncological approach, and a radical exeresis was always
performed. The presence of metastatic lymphadeno-
pathies was taken as the only predictive outcome fac-
tor. Other factors, e.g., histology, were not found to
have much weight as a predictive factor. 
In our study, the number of lymph nodes exami-
ned did not have an impact on survival. This is in
contrast with other studies that showed that the pro-
gnosis would depend on the number of lymph nodes
examined (21). According to Way et al., the number
of lymph nodes affected, along with the patient’s
age, were significant factors for the patient’s survival. 
Some authors place as significant factors for survi-
val the presurgical CEA values and the patient’s gender
(22-23). For us, according to oncologists at internatio-
nal level, the CEA must be examined as a predictive of
recurrence and not as a diagnostic tool, we have exa-
mined the CEA presurgically just to obtain a value at
this stage. The gender is also not significant for us. 
In conclusion, the incidence of lymph node meta-
stases in patients with pT1 and pT2 cancer is impor-
tant as predictive factor for survival and recurrence.
Neither the lymphovascular permeation nor the CEA
are factors that may affect survival. Clearly, radical sur-
gery, even with T1 and T2 cancer is fundamentally
and must always be ensured. The presence of metasta-
tic lymphadenopathy is one further reason to require a
throughout follow up.
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